• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Jan De Witte joins GHO Capital as Operating Partner

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IART alert in real time by email

    Jan De Witte joins GHO Capital as Operating Partner

    Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio

    London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner.

    Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integra", NASDAQ:IART), a global leader in regenerative tissue technologies, and neurosurgical and ENT solutions. At Integra Jan drove international expansion and operational excellence, and through strategic acquisitions and innovation added $1 billion to the total addressable market of the company's offerings.

    Prior to Integra, Jan served as CEO of Barco N.V. (EBR: BAR), directing the advanced visualisation technology company's digital transformation and global market expansion. He strengthened Barco's position in the healthcare, entertainment, and enterprise sectors through new product launches and operational improvements and global market expansions. Earlier in his career, he spent 18 years at GE Healthcare leading global teams in Digital Health, Services, Manufacturing, Quality and Supply Chain across the Americas, EMEA, and Asia. Jan's career started with foundational roles in Operations at Procter & Gamble and as Senior Consultant at McKinsey in Europe.

    Jan currently serves as a Director of ResMed Inc. (NYSE:RMD), a digital health and medical device leader. His board experience includes previous roles at Barco N.V. and international joint ventures. He holds an M.B.A. from Harvard Business School and Master's and Bachelor's degrees in electromechanical engineering with highest distinction from KU Leuven, Belgium.

    As Operating Partner, Jan will leverage his extensive leadership experience and global network to support and grow GHO's portfolio companies, as well as supporting with the firm's transatlantic deal origination.

    The Partners at GHO Capital commented: "Jan brings a wealth of healthcare industry expertise and a strong track record to our team as we look to implement our proven operational playbook and drive expansion and growth across our portfolio. The healthcare sector is experiencing significant innovation, supported by favourable market conditions, and Jan's experience will help us identify businesses with the most substantial growth potential. On behalf of the entire GHO team, we warmly welcome him and look forward to the positive impact he will make."

    Commenting on his new appointment, Jan De Witte, Operating Partner at GHO Capital, said: "My focus throughout my career has always been to support innovative healthcare companies as they grow and transform, whilst creating long-term investor value. I am excited to be joining GHO Capital, one of Europe's leading healthcare specialist private equity firms, who are committed to driving the highest standards across the healthcare sector. I look forward to working with the team and leveraging my expertise to support GHO's portfolio companies realise their full potential."

    -Ends-

    Further information:

    GHO Capital Partners LLP

    T +44 20 3700 7440

    E [email protected]

    For Media Enquiries



    ICR Healthcare



    Amber Fennell, Angela Gray, Kris Lam











    Tel: +44 (0) 20 3709 5700



    [email protected]







    About GHO Capital

    Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital's proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.



    Primary Logo

    Get the next $IART alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IART
    $RMD

    CompanyDatePrice TargetRatingAnalyst
    Integra LifeSciences Holdings Corporation
    $IART
    3/31/2025Hold → Buy
    Argus
    ResMed Inc.
    $RMD
    3/19/2025$280.00Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    3/19/2025Overweight
    Morgan Stanley
    ResMed Inc.
    $RMD
    1/16/2025Buy
    Goldman
    ResMed Inc.
    $RMD
    1/10/2025$252.00Neutral
    Piper Sandler
    ResMed Inc.
    $RMD
    12/13/2024$250.00Hold
    Stifel
    Integra LifeSciences Holdings Corporation
    $IART
    12/2/2024$25.00 → $20.00Underweight
    Morgan Stanley
    Integra LifeSciences Holdings Corporation
    $IART
    10/7/2024Sell → Neutral
    BTIG Research
    More analyst ratings

    $IART
    $RMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Essig Stuart bought $1,499,979 worth of shares (52,641 units at $28.49), increasing direct ownership by 12% to 487,922 units (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/24/24 4:08:19 PM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Hill Barbara B bought $995,816 worth of shares (36,350 units at $27.40) (SEC Form 4)

      4 - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Issuer)

      5/22/24 4:09:18 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Resmed Champions Sleep Health as The Official Sleep Partner of The Qatar Airways British & Irish Lions Tour to Australia 2025

      SAN DIEGO and LONDON and DUBLIN and SYDNEY, May 15, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, has been named the Official Sleep Partner of the Qatar Airways British & Irish Lions Tour to Australia. The Tour brings rugby fans' dreams to life over a six-week period. For the first time in 12 years, The Lions squad, alongside an estimated 40,000 fans, will battle it out with the Wallabies, Super Rugby Pacific teams, and exhibition sides in six cities across Australia. As the Official Sleep Partner, Resmed will launch ‘Tackle Your Sleep,' a digital and content focused campaign featu

      5/15/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Reports First Quarter 2025 Financial Results

      PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025. First Quarter 2025 Highlights First quarter revenues of $382.7 million increased 3.7% on a reported basis and decreased 3.5% on an organic basis compared to the prior year. First quarter GAAP earnings per diluted share of $(0.33), compared to $(0.04) in the prior year; adjusted earnings per diluted share of $0.41, compared to $0.55 in the prior year.Reaffirming full-year 2025 revenue guidance range and updating adjusted EPS guidance to account for the impact

      5/5/25 6:30:00 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Resmed Acquires VirtuOx

      SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced it has acquired VirtuOx, a leading independent diagnostic testing facility (IDTF) for sleep, respiratory, and cardiac conditions. The acquisition reflects Resmed's commitment to improving the way care is delivered—by making it more accessible, more coordinated, and more patient friendly. With VirtuOx's at-home diagnostic services, Resmed will be better positioned to support patients earlier in their journey and help healthcare providers and homecare companies deliver care in a simpler, more connected wa

      5/1/25 9:00:00 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $IART
    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Farrell Michael J. exercised 8,009 units of ResMed Common Stock at a strike of $101.64 and sold $2,011,910 worth of ResMed Common Stock (8,009 units at $251.21) (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      6/10/25 6:35:44 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Director Farrell Peter C sold $494,640 worth of ResMed Common Stock (2,000 units at $247.32), decreasing direct ownership by 3% to 69,218 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      6/6/25 3:22:36 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Sandercock Brett sold $243,780 worth of ResMed Common Stock (1,000 units at $243.78), decreasing direct ownership by 1% to 85,283 units (SEC Form 4)

      4 - RESMED INC (0000943819) (Issuer)

      6/3/25 5:59:17 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $IART
    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Integra upgraded by Argus

      Argus upgraded Integra from Hold to Buy

      3/31/25 8:28:08 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed with a new price target

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight and set a new price target of $280.00

      3/19/25 10:13:23 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on ResMed

      Morgan Stanley initiated coverage of ResMed with a rating of Overweight

      3/19/25 8:18:03 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care

    $IART
    $RMD
    SEC Filings

    See more
    • SEC Form 144 filed by ResMed Inc.

      144 - RESMED INC (0000943819) (Subject)

      6/9/25 10:26:33 AM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Integra LifeSciences Holdings Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      6/9/25 6:30:24 AM ET
      $IART
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Integra LifeSciences Holdings Corporation

      SD - INTEGRA LIFESCIENCES HOLDINGS CORP (0000917520) (Filer)

      5/30/25 4:44:55 PM ET
      $IART
      Medical/Dental Instruments
      Health Care

    $IART
    $RMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Resmed Names Salli Schwartz as Chief Investor Relations Officer

      SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

      4/21/25 5:00:00 PM ET
      $RMD
      Medical/Dental Instruments
      Health Care
    • Jan De Witte joins GHO Capital as Operating Partner

      Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

      2/11/25 4:30:00 AM ET
      $IART
      $RMD
      Medical/Dental Instruments
      Health Care
    • Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

      NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

      2/4/25 9:15:00 AM ET
      $IXHL
      $RMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments